Novo Nordisk A/S (NVO)
-NYSE 172.32 
0.17(0.10%) 4:03PM EDT
| Prev Close: | 172.15 |
|---|
| Open: | 171.50 |
|---|
| Bid: | 169.00 x 100 |
|---|
| Ask: | 174.00 x 500 |
|---|
| 1y Target Est: | 199.15 |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 171.39 - 173.02 |
|---|
| 52wk Range: | 129.41 - 194.44 |
|---|
| Volume: | 147,115 |
|---|
| Avg Vol (3m): | 364,064 |
|---|
| Market Cap: | 93.50B |
|---|
| P/E (ttm): | 25.56 |
|---|
| EPS (ttm): | 6.74 |
|---|
| Div & Yield: | 2.26 (1.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- One Soda a Day Keeps Your Health Awayat Motley Fool(Thu 1:36PM EDT)
- Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu 1:20PM EDT)
- David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in GenericsWall Street Transcript(Thu 11:08AM EDT)
- Earnings and Sales Rise at Novo NordiskZacks(Thu 8:25AM EDT)
- Novo Nordisk A/S (NVO): Today's Featured Health Care Laggardat TheStreet(Wed, May 1)
- Novo Nordisk A/S Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Novo Nordisk and EMIS Modify DealZacks(Wed, May 1)
- Wall Street Breakfast: Must-Know Newsat Seeking Alpha(Wed, May 1)
- InPlay: Novo Nordisk A/S beats by DKK0.31, beats on revs; guides FY13 revs above consensusBriefing.com(Wed, May 1)
- Novo Nordisk A/S Rises On Unusually High Volume (NVO)at TheStreet(Mon, Apr 29)
- Emisphere Announces Amendment to Oral GLP-1 Development License Agreement With Novo NordiskGlobeNewswire(Mon, Apr 29)
- Trounce the Market With This Diabetes Care Companyat Motley Fool(Sun, Apr 28)
- Wall Street Transcript Interview with Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY)Wall Street Transcript(Fri, Apr 26)
- "The Most Sustainable Company in the World"at Motley Fool(Thu, Apr 25)
- Novo Nordisk A/S (NVO): Today's Featured Health Care Winnerat TheStreet(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | 21.43 |
|---|
| P/S (ttm): | 6.90 |
|---|
| Ex-Dividend Date: | 21-Mar-13 |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(Jun-12)
: | N/A |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals.
View More